Molecules 2008, 13(1), 46-68; doi:10.3390/molecules13010046
Review

Antiparkinson Prodrugs

Department of Drug Sciences, “G. d'Annunzio” University, School of Pharmacy, Via dei Vestini 31, 66100 Chieti, Italy
* Author to whom correspondence should be addressed.
Received: 4 December 2007; in revised form: 11 January 2008 / Accepted: 11 January 2008 / Published: 16 January 2008
(This article belongs to the Special Issue Prodrugs)
PDF Full-text Download PDF Full-Text [183 KB, uploaded 1 October 2008 09:18 CEST]
Abstract: Parkinson`s disease (PD) is a progressive, neurodegenerative disorder whichinvolves the loss of dopaminergic neurons of the substantia nigra pars compacta. Currenttherapy is essentially symptomatic, and L-Dopa (LD), the direct precursor of dopamine(DA), is the treatment of choice in more advanced stages of the disease. Substitutiontherapy with LD is, however, associated with a number of acute problems. The peripheralconversion of LD by amino acid decarboxylase (AADC) to DA is responsible for thetypical gastrointestinal (nausea, emesis) and cardiovascular (arrhythmia, hypotension) sideeffects. To minimize the conversion to DA outside the central nervous system (CNS) LD isusually given in combination with peripheral inhibitors of AADC (carbidopa andbenserazide). In spite of that, other central nervous side effects such as dyskinesia, on-offphenomenon and end-of-dose deterioration still remain. The main factors responsible forthe poor bioavailability and the wide range of inter- and intra-patient variations of plasmalevels are the drug’s physical-chemical properties: low water and lipid solubility, resultingin unfavourable partition, and the high susceptibility to chemical and enzymaticdegradation. In order to improve the bioavailability, the prodrug approach appeared to bethe most promising and some LD prodrugs have been prepared in an effort to solve theseproblems. We report here a review of progress in antiparkinson prodrugs, focusing onchemical structures mainly related to LD, DA and dopaminergic agonists.
Keywords: L-dopa; Dopamine; Prodrugs; antiparkinson

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Di Stefano, A.; Sozio, P.; Cerasa, L.S. Antiparkinson Prodrugs. Molecules 2008, 13, 46-68.

AMA Style

Di Stefano A, Sozio P, Cerasa LS. Antiparkinson Prodrugs. Molecules. 2008; 13(1):46-68.

Chicago/Turabian Style

Di Stefano, Antonio; Sozio, Piera; Cerasa, Laura S. 2008. "Antiparkinson Prodrugs." Molecules 13, no. 1: 46-68.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert